Interrogating antiviral antibody responses with multiplexed, high-throughput serum assays

Abstract The COVID-19 pandemic underscored the importance of rapidly analyzing antibody responses against emerging viruses. Existing techniques, however, are limited in their ability to probe antibodies’ recognition of multiple native-conformation antigens simultaneously. To increase the throughput and multiplexability of antibody profiling, we developed Antibody Reactivity Characterization by Antibody-Dependent Enhancement (ARCADE). This assay employs an antigen-agnostic Fc receptor-expressing cell line and a library of antigen-displaying, genetically barcoded lentiviruses that, when mixed with serum, infect cells and integrate their barcodes at rates reflecting the relative abundances and affinities of the antigen-specific antibodies present. Verified using sera from COVID-19-convalescent and - vaccinated donors, ARCADE delivers insights that align with and expand upon those offered by established immunoassays, highlighting, for example, how an mRNA-based vaccine elicits broader and stronger antibody responses than an adenovirus vector-based vaccine. ARCADE can comprehensively assess how infection and vaccination impact antiviral antibody repertoires over time and across patient populations. Competing Interest Statement M.E.B. is a co-founder, board member, and equity holder of Kelonia Therapeutics. M.E.B. and C.S.D. are co-inventors on patents related to the lentiviral pseudotyping strategy enabling this work. C.S.D. is a current employee of Johnson & Johnson. M.E.B. has received research funding from Pfizer unrelated to this work. The remaining authors have no competing interests.